PARK7 and cancer: Overall, the pharmaceutical or genetic activation/suppression of DJ-1 in combination with other therapies (such as immuno-oncology) will open up new avenues for the treatment of various intractable human diseases other than cancer and PD (such as gut–brain axis diseases and ischemia–reperfusion injury) [87,88].